United Therapeutics Corporation
UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exerciseā¦ read more
Healthcare
Biotechnology
26 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$575.79
Price-0.65%
-$3.75
1Y
Price
Market Cap
$24.440b
Large
Price/Earnings 3y Avg5y Avg
21.3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+44.6%
EBITDA Margin+35.2%
Net Profit Margin+46.4%
Free Cash Flow Margin+44.6%
EBITDA Margin+35.2%
Net Profit Margin+46.4%
Free Cash Flow MarginRevenue
$3.170b
-0.4%
1y CAGR+11.3%
3y CAGR+13.5%
5y CAGREarnings
$1.287b
-3.5%
1y CAGR+9.8%
3y CAGR+16.2%
5y CAGREPS
$27.05
-2.9%
1y CAGR+11.5%
3y CAGR+16.7%
5y CAGRBook Value
$5.901b
$6.714b
Assets$813.100m
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
$1.017b
-2.3%
1y CAGR+12.9%
3y CAGR+12.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company